NewAmsterdam Pharma (NASDAQ:NAMSW) Sees Significant Growth in Short Interest

NewAmsterdam Pharma (NASDAQ:NAMSW) was the recipient of a large increase in short interest during the month of May. As of May 29th, there was short interest totaling 71 shares, an increase of 69.0% from the May 14th total of 42 shares. Based on an average daily trading volume, of 250 shares, the days-to-cover ratio is currently 0.3 days.

NewAmsterdam Pharma Stock Down 0.5%

NAMSW stock traded down $0.10 on Tuesday, hitting $18.70. 652 shares of the company’s stock were exchanged, compared to its average volume of 1,926. NewAmsterdam Pharma has a 12-month low of $7.80 and a 12-month high of $30.45. The firm has a 50 day moving average price of $22.70 and a two-hundred day moving average price of $22.69.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NewAmsterdam Pharma stock. Aristeia Capital L.L.C. bought a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMSW) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 15,708 shares of the company’s stock, valued at approximately $397,000.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.

The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.